Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q4 Sales Top Estimates
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results exceeding the market’s revenue expectations, ...
kalkinemedia4 天
How Is Vertex Inc. (NASDAQ:VERX) Expanding Its Market Presence
Highlights,Increased institutional ownership in Vertex Inc. with notable transactions recorded.,Strong year-over-year revenue ...
Vertex Forecasts Upbeat 2025 Revenue on Cystic Fibrosis Treatments Demand
Vertex sees 2025 revenue of $11.75 billion to $12.0 billion, the midpoint of which is above analysts' average expectation of ...
Scientific American3 天
How Can We Know If an Asteroid Will Hit Earth?
Keep your eye on the ball” is a motto for many athletes—and for astronomers trying to find Earth-threatening space rocks ...
Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?
The fourth-quarter earnings season for the biotech sector is in full swing this week. A few bigwigs have already reported ...
The FDA just approved a new painkiller. Is it too good to be true?
Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...
Google Gemini 2.0 is now free for users — here’s how to access it now
The Gemini 2.0 Flash model is also now generally available through the Gemini API in Google AI Studio and Vertex AI. This ...
Vertex Pharmaceuticals' SWOT analysis: biotech giant's stock faces growth challenges
Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...
Top Wall Street Forecasters Revamp Vertex Pharmaceuticals Price Expectations Ahead Of Q4 ...
Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.02 per share, down from $4.20 per share in the year-ago period. Vertex Pharmaceuticals projects quarterly ...